@article{ref1,
title="In vivo evidence for dysregulation of mGluR5 as a biomarker of suicidal ideation",
journal="Proceedings of the National Academy of Sciences of the United States of America",
year="2019",
author="Davis, Margaret T. and Hillmer, Ansel and Holmes, Sophie E. and Pietrzak, Robert H. and DellaGioia, Nicole and Nabulsi, Nabeel and Matuskey, David and Angarita, Gustavo and Carson, Richard E. and Krystal, John H. and Esterlis, Irina",
volume="116",
number="23",
pages="11490-11495",
abstract="Recent evidence implicates dysregulation of metabotropic glutamatergic receptor 5 (mGluR5) in pathophysiology of PTSD and suicidality. Using positron emission tomography and [18F]FPEB, we quantified mGluR5 availability in vivo in individuals with PTSD (n = 29) and MDD (n = 29) as a function of suicidal ideation (SI) to compare with that of healthy comparison controls (HC; n = 29). Volume of distribution was computed using a venous input function in the five key frontal and limbic brain regions. We observed significantly higher mGluR5 availability in PTSD compared with HC individuals in all regions of interest (P's = 0.001-0.01) and compared with MDD individuals in three regions (P's = 0.007). mGluR5 availability was not significantly different between MDD and HC individuals (P = 0.17). Importantly, we observed an up-regulation in mGluR5 availability in the PTSD-SI group (P's = 0.001-0.007) compared with PTSD individuals without SI. <br><br>FINDINGS point to the potential role for mGluR5 as a target for intervention and, potentially, suicide risk management in PTSD.<p /><p>Language: en</p>",
language="en",
issn="0027-8424",
doi="10.1073/pnas.1818871116",
url="http://dx.doi.org/10.1073/pnas.1818871116"
}